āagman

Not investment advice. Data and computed figures, for information only.

Fortis Healthcare Ltd

NSE: FORTISF&O
₹746.25
−₹3.75 (−0.50%)
NSE · 15 Oct 2026, close
NSE
As of 31 Mar 2026
Market Cap
₹59,359 Cr
CMP
₹746.25
52-wk High / Low
₹1,104 / 738
P/E
55.6
P/B
6.0
Book Value
₹131.0
Div Yield
0.13%
ROCE
13.0%
ROE
11.2%
Face Value
₹10
D/E
0.35

Price−29.6% over 1Y

āagman read

Computed by āagman
Derived from 12 years and 15 quarters of filings. Not reported by the company.
As of 15 Oct 2026
How we compute these
Piotroski F-Score
6
/ 9
6 of 9 F-score tests passed
Graham Number
₹202
√(22.5 × EPS × book value per share)
ROIC
9.5%
vs 11.2% sector median
Cash flow to profit
1.50
CFO / PAT
Above 1.0 = operating cash flow exceeded reported profit
Margin change
−156
bps OPM YoY
Operating margin vs the same quarter last year
Sustainable growth
10.4%
ROE × earnings retention ratio
ROE stability
1.6
pp σ
Standard deviation of ROE across periods. Lower = more stable
Holder deltas
QoQ
pp
Prom +0.00FII −0.78DII +0.88
Latest quarter vs the previous one
Cash-accrual divergence
−3.7%
of assets
Low = accruals track cash flow
Strengths
Watch-outs
−Latest ROCE of 13% trails the sector median of 17%
−Borrowings are up 129.5% since FY2016 (1513 to 3473)
−Price trades below its 200-day moving average (0.8x)
−Price is 32.4% below its 52-week high

Peer comparison

Peers
NameP/EMar Cap ₹ CrROCE %ROE %

Quarterly results

Consolidated basis (as filed) · ₹ Cr · 13 quarters
As of 30 Jun 2026
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,6571,7701,6801,7861,8591,9881,9282,0072,1672,3312,2652,3652,545
Expenses1,3861,4401,3961,4051,5161,5541,5531,5721,6761,7751,7591,8322,008
Operating Profit272330284381343435375435491556506532537
OPM %16.4%18.6%16.9%21.3%18.5%21.9%19.5%21.7%22.7%23.9%22.3%22.5%21.1%
Other Income1018191714−4247−293150−34−228
Interest31323335353645687075868480
Depreciation79848792919597102101106120122122
Profit before tax171233183271230261279237351425266324363
Net Profit124184134203174193254188267329197271273
EPS (₹)1.482.301.782.372.202.343.282.443.454.262.573.523.53

Profit & Loss

As of 30 Jun 2026
Consolidated · ₹ Cr · 12 years + TTM
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales3,9664,1994,5744,5614,4694,6324,0305,7186,2986,8937,7839,1289,506
Expenses3,8574,1064,2204,2874,2384,0223,6264,6495,1965,6256,1957,0437,375
Operating Profit109923542742316104041,0691,1011,2681,5882,0852,131
OPM %2.7%2.2%7.7%6.0%5.2%13.2%10.0%18.7%17.5%18.4%20.4%22.8%22.4%
Other Income92299649−6892281269536715764−114542
Interest152133229258337205166147129131184314325
Depreciation235225222239233292291301316342386449470
Profit before tax−18534552−912−110239439888148581,0071,3661,378
Net Profit−13042479−934−22491−567906336458091,0641,070
EPS (₹)−3.100.408.14−19.46−3.960.77−1.457.357.807.9310.2613.8013.88

Balance Sheet

As of 30 Jun 2026
Consolidated · ₹ Cr
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Jun 2026
Equity Capital463463518519755755755755755755755755—
Reserves3,5853,9984,6263,5435,8465,9065,3655,4236,4876,9088,1629,141—
Borrowings1,7841,5132,2171,9622,0101,5941,5311,2559261,1552,4753,473—
Other Liabilities1,7601,2572,2272,4552,8752,7813,2164,0823,9214,1531,9852,465—
Total Liabilities7,5927,2329,5888,47911,48611,03610,86611,51612,08912,97113,37715,833—
Fixed Assets4,2183,6425,4194,9928,4778,8028,7999,4169,4269,87410,42412,230—
CWIP228226268226450204165193228542407434—
Investments1,4641,4521,8781,732270175186104210230169243—
Other Assets1,6821,9132,0231,5292,2901,8561,7161,8032,2252,3262,3782,926—
Total Assets7,5927,2329,5888,47911,48611,03610,86611,51612,08912,97113,37715,833—

Cash Flows

As of 31 Mar 2026
Consolidated · ₹ Cr
Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity47924195966493−1791724858658221,1001,4241,601
Cash from Investing Activity2,503213122−1,001−333−3,27963−131−501−372−889−780−1,537
Cash from Financing Activity−3,217−304−354259−6724,257−862−143−517−471−86−714164
Net Cash Flow−235−66−37225−513799−627212−153−21125−70228

Ratios

As of 31 Mar 2026
13 periods
Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %0.00.03.011.03.06.04.02.010.010.010.012.013.0
ROE %————————————11.2
EPS (₹)−4.73−3.100.408.14−19.46−3.960.77−1.457.357.807.9310.2613.80
Book Value (₹)————————————131.0
Face Value (₹)————————————10
P/E————————————55.6
Div Yield %————————————0.13
NPM %−6.2−3.20.99.2−24.1−4.81.9−1.413.09.89.310.411.6
OPM %2.02.82.28.06.05.013.010.019.017.018.020.023.0
D/E0.600.440.340.430.480.300.240.250.200.130.150.280.35
P/B————————————6.0

Growth

As of 11 Oct 2026
Compounded sales growth
10 years+8.0%
5 years+18.0%
3 years+13.0%
TTM+18.0%
Compounded profit growth
10 years+60.0%
5 years+64.0%
3 years+27.0%
TTM+16.0%
Stock price CAGR
10 years+17.0%
5 years+25.0%
3 years+33.0%
Last year−26.0%
Return on equity
10 years5.0%
5 years9.0%
3 years10.0%
Last year11.0%

Shareholding pattern

As of 31 Mar 2026
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters52.30%52.30%0.77%31.33%31.17%31.17%31.17%31.17%31.17%31.17%31.17%31.17%
FIIs34.50%34.50%45.63%39.72%43.13%34.42%29.82%31.22%23.24%27.40%25.98%25.20%
DIIs0.40%0.40%21.91%11.23%8.45%13.57%16.90%20.69%31.14%29.46%31.35%32.23%
Government————————————
Public12.80%12.80%31.69%17.73%17.25%20.84%22.12%16.92%14.44%11.98%11.50%11.40%
No. of shareholders1,10,9011,10,9011,32,2251,16,9431,03,8111,09,8891,56,8811,37,8941,57,1652,18,3292,26,6852,20,743
Change since Jun 2023 (pp)
Promoters −21.13FIIs −9.30DIIs +31.83Public −1.40

Documents

As of 11 Oct 2026
Announcements
Announcement / Press Release Filed By IHH Healthcare Berhad ('IHH')Update On Special Leave Petition (''SLP'') Filed By The Company Before The Hon''ble Supreme Court Of IndiaClosure of Trading WindowUpdate On Material Litigation Filed By Northern TK Venture Pte Ltd. (''NTK''), The Promoter Shareholder Of The Company, Against Daiichi Sankyo Company, Limited Before The Tokyo District Court In JapanAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
Annual reports
Annual Report 2026Annual Report 2025Annual Report 2024Annual Report 2023Annual Report 2022
Credit ratings
Rating updateRating updateRating updateRating updateRating update
Concalls
Sep 2026TranscriptSep 2026RecordingAug 2026TranscriptAug 2026PPTAug 2026RecordingMay 2026TranscriptMay 2026PPTFeb 2026TranscriptFeb 2026PPTFeb 2026RecordingJan 2026PPT

Corporate actions

As of 24 Jul 2026
24 Jul 2026DIVIDENDDividend - Re 1 Per Share—
25 Jul 2025DIVIDENDDividend - Re 1 Per Share—
24 Jul 2024DIVIDENDDividend - Re 1 Per Share—
20 Jul 2023DIVIDENDDividend - Re 1 Per Share—
Fundamentals from a third-party compiler of exchange filings; prices from the exchanges. Not investment advice.© 2026 āagman